All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | Blinatumomab added to prephase and consolidation phase in newly diagnosed patients with ALL: HOVON146ALL
Bookmark this article
The ALL Hub is pleased to present a visual abstract representing key data from the phase II HOVON146ALL trial (NCT03541083), evaluating blinatumomab added to prephase and consolidation therapy in newly diagnosed patients with ALL.
More about...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox